LEADING EXTRACELLULAR VESICLE RESEARCH TOWARDS THE NEXT GENERATION OF TREATMENTS AND DIAGNOSTICS
With
Associate Professor Joy Wolfram, Group Leader,
Australian Institute for Bioengineering and Nanotechnology,
School of Chemical Engineering, University of Queensland
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Brisbane | May 2025
Joy Wolfram is an Associate Professor at the Australian Institute for Bioengineering and Nanotechnology and the School of Chemical Engineering at the University of Queensland in Australia. Originally from Finland, she earned both her bachelor’s and master’s degrees in biology before transitioning to engineering with a PhD in nanotechnology completed in China. Wolfram has over a decade of experience working in hospitals in the United States before joining the University of Queensland.
Her research focuses on extracellular vesicles, which are crucial for cell communication both locally within tissues and over longer distances between organs. Her lab studies the roles of these vesicles in both health and disease, particularly in cancer. They investigate the harmful messages released by cancer cells that aid in tumour growth, specifically in breast cancer, while also exploring how to harness beneficial extracellular vesicles from healthy individuals as potential therapeutics.
Wolfram’s lab is currently funded by the National Breast Cancer Foundation for a four-year project aimed at understanding how breast cancer-derived vesicles evade the immune system. Collaborations with the Faculty of Medicine and hospitals in the U.S. enhance her research efforts. Additionally, partnerships with local industries in Brisbane, supported by the Medical Research Future Fund, promote academia-industry connections. Notably, funding from Health Translation Queensland allows her to compensate patient advocates who contribute valuable insights and direction to her research.
Source: Written by AUDIENCED from transcript
-
Pharmacist Prescribing Model gets further support from state health
A full scope pharmacist prescriber model allows pharmacists to independently prescribe medicines within their professional competence, without requiring prior doctor authorisation. It extends pharmacists’ role beyond dispensing to include assessment, diagnosis of minor and chronic conditions, initiation and modification of therapy, and ongoing patient monitoring. This model integrates pharmacists into primary care teams, aiming to improve timely access to treatment, reduce pressure on general practitioners, and enhance continuity of care. Pharmacists use their clinical knowledge, patient records, and collaborative pathways to ensure safe prescribing. The model emphasises training, regulation, and accountability to maintain high standards of patient safety.
-
Reflecting on a pivotal year for pharmacy
Dr. Kate Wang, a Senior Lecturer in Pharmacy at RMIT University and Adjunct Senior Lecturer, University of Western Australia, has over a decade of experience in both hospital and community pharmacy settings.
Dr Wang spoke to Australian Health Journal on some of the key topics in 2024 that have been pivotal as a pharmacist, academic and researcher for the pharmacy profession.
-
The desire for primary care nurses to do more, be recognised and valued for the work they do
Denise Lyons is a highly experienced nurse with over 40 years in the profession, including more than 25 years dedicated to primary care. She earned her Bachelor of Science in Nursing in the United States in 1985 and, in 2012, became an endorsed Nurse Practitioner in Australia. Currently, she serves as a primary care Nurse Practitioner in General Practice in Newcastle, where she is committed to delivering high-quality, patient-centred care that improves the health and wellbeing of her community.
